Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SL-172154 (Shattuck Labs)
- Development stage
- Unknown
- Lead developer
- Shattuck Labs
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intratumoral
01
Overview
SL-172154 is a first-in-class bifunctional fusion protein designed to simultaneously inhibit the immunosuppressive TGF-β pathway and activate the OX40 costimulatory pathway. It consists of the extracellular domain of the Type II TGF-β receptor (TGFβRII) fused to the OX40 ligand (OX40L) via a central Fc domain. By sequestering TGF-β1 and TGF-β3, it prevents TGF-β-mediated immune evasion and fibrosis in the tumor microenvironment. Simultaneously, the OX40L component binds to OX40 on T cells and natural killer (NK) cells, promoting their activation, proliferation, and survival. This dual mechanism aims to convert immunosuppressive "cold" tumors into immune-active "hot" tumors. It is being developed by Shattuck Labs for the treatment of various solid tumors and hematologic malignancies.
- Other names
- TGFβRII-Fc-OX40LTGF-beta receptor II/OX40L fusion protein
02
Targets
CD40 (Cluster of differentiation 40 receptor)CD47 (Cluster of Differentiation 47)TGFB1 (Transforming growth factor Beta-1 proprotein)TGFB3 (Transforming growth factor beta 3)CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on SL-172154 (Shattuck Labs).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SL-172154 (Shattuck Labs).